Trial Profile

A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms JAVELIN Lung 100
Sponsors EMD Serono; EMD Serono Research & Development Institute; Merck KGaA

Most Recent Events

19 Feb 2024 Status changed from active, no longer recruiting to completed.
06 Feb 2024 This study has been completed in Cyprus, according to European Clinical Trials Database record.
27 Jan 2024 This study has been completed in Hungary, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com